跳至主要内容
临床试验/CTIS2024-516282-37-00
CTIS2024-516282-37-00进行中(未招募)1 期

Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, Prior Chemotherapy for Breast Cancer (PRESAGE) - ICO-N-2013-03

Institut De Cancerologie De L Ouest0 个研究点目标入组 100 人开始时间: 2024年7月11日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)

入选标准

  • 1.Obtaining signed informed consent prior to any trial-specific procedure, 10.Social protection, 2.Between 18 and 40 yo, 3.Histologically proven invasive breast carcinoma, 4.Indication for adjuvant or neoadjuvant chemotherapy validated by pre-therapy PCR, 5.T0-T1-T2-T3, 6.N0-N1-N2a, 7.M0 after extension assessment according to French INCa recommendations, 8.AMH (anti-müllerian hormone) =1 ng/mL and/or AFC (antral follicle count) = 5 (on ultrasound: ovaries puncturable transvaginally),, 9.HIV serology negative

排除标准

  • 1.Previous breast cancer, 2.History of any other cancer in the last 5 years, with the exception of basal cell and squamous cell skin cancers, 3.Pregnancy in progress, 4.Pulmonary embolism less than 6 months old, 5.Deep vein thrombosis less than 6 months old, 6.Dementia or altered mental state, 7.Legal incapacity or limited legal capacity. Medical or psychological conditions preventing the subject from understanding the study and signing the consent form (art. L.1121-6, L.1211-8, L.1211-9).

研究者

相似试验